CTEP Branches and Offices
NCI Experimental Therapeutics Clinical Trials Network (ETCTN)
- Overview/Objectives
- Participating Clinical Sites
- Infrastructure
- ETCTN Trials
- ETCTN Publication Policy
- ETCTN Monitoring Guidelines
- Interventional Radiology SOP
- EDDOP-ETCTN Leadership Program Supplement
- Institutional Certification and HMTA for ETCTN Trials
2019 FOAs for the ETCTN and PK Resource Laboratories
- Q&A (Questions & Answers) regarding the FOAs
- ETCTN FOA
- PK Resource Laboratories FOA
- Correction Notice for the PK Resource Laboratories FOA
Pre-application Webinar on Feb. 6, 2019, for ETCTN and PK Resources Laboratories
- Slides from ETCTN FOA Webinar
- Webinar Notice
- Pre-application Webinar for the ETCTN and the ETCTN Pharmacokinetic Resource Laboratories (2 hr 6 min)
Overview/Objectives
The National Cancer Institute (NCI) has formed partnerships in the pharmaceutical industry, academic institutions, and individual investigators for the early clinical evaluation of innovative cancer therapies. The Experimental Therapeutics Clinical Trials Network (ETCTN) was created to evaluate these therapies using a coordinated, collaborative, and inclusive team-based approach to early phase experimental therapeutic clinical trials.
The objectives of the ETCTN are to:
- Conduct early clinical trials of NCI-IND agents in high priority areas of unmet medical needs
- Ensure efficient and timely activation and conduct of these clinical trials
- Integrate preclinical findings using clinical samples for biomarker analysis
- Promote collaboration among institutions and investigators
- Integrate molecular characterization, pharmacology, cancer biology, and imaging into clinical trials
See the links in the sidebar for more information about the ETCTN.
ETCTN Participating Sites
ETCTN Phase 1 and Phase 2 Program Sites
ETCTN clinical sites (see map above) participate in a Phase 1 Program supported by UM1 grants, integrated with a Phase 2 Program supported by cooperative agreements as supplements to the existing phase 1 UM1 grant. By integrating Phase 1 and Phase 2 Program activities and administrative operations under the UM1 structure, ETCTN awardees will have the flexibility to expand phase 1 studies quickly upon detecting early activity signals.
University Health Network Princess Margaret Cancer Center LAO |
University Health Network-Princess Margaret Hospital |
BCCA-Vancouver Cancer Centre |
BCCA-Vancouver Island Cancer Centre |
BCCA-Fraser Valley Cancer Centre |
BCCA-Cancer Centre for the Southern Interior |
BCCA-Abbotsford Cancer Centre |
BCCA-Cancer Centre for the North |
Moffitt Cancer Center |
Moffitt Cancer Center-International Plaza |
Virginia Commonwealth University/Massey Cancer Center |
City of Hope Comprehensive Cancer Center LAO |
City of Hope Comprehensive Cancer Center |
City of Hope South Pasadena |
City of Hope Antelope Valley |
USC / Norris Comprehensive Cancer Center |
Children's Hospital of Los Angeles |
Los Angeles County-USC Medical Center |
Keck Medical Center of USC Pasadena |
Stanford Cancer Institute |
University of California Davis Comprehensive Cancer Center |
Yale University Cancer Center LAO |
Yale University |
Smilow Cancer Hospital Care Center at Saint Francis |
Smilow Cancer Center/Yale-New Haven Hospital |
Smilow Cancer Hospital - Torrington Care Center |
Smilow Cancer Hospital Care Center - Trumbull |
Yale-New Haven Shoreline Medical Center |
Smilow Cancer Hospital - Waterbury Care Center |
Smilow Cancer Hospital - Orange Care Center |
Smilow Cancer Hospital - DerbyCare Center |
Yale-New Haven Hospital North Haven Medical Center |
Lawrence and Memorial Cancer Center |
Smilow Cancer Hospital Care Center - Fairfield |
Wayne State University/Karmanos Cancer Institute |
Vanderbilt University/Ingram Cancer Center |
UC San Diego Moores Cancer Center |
University of California San Diego |
UCSF Medical Center-Mission Bay |
UCSF Medical Center-Parnassus |
UCSF Medical Center-Mount Zion |
Translational Genomics Research Institute |
Dana-Farber - Harvard Cancer Center LAO |
Dana-Farber/Harvard Cancer Center |
Brigham and Women's Hospital |
Beth Israel Deaconess Medical Center |
Massachusetts General Hospital Cancer Center |
JHU Sidney Kimmel Comprehensive Cancer Center LAO |
Johns Hopkins University/Sidney Kimmel Cancer Center |
Sibley Memorial Hospital |
Suburban Hospital |
Johns Hopkins Bayview Medical Center |
MedStar Georgetown University Hospital |
Emory University/Winship Cancer Institute |
Emory University Hospital Midtown |
Memorial Sloan Kettering Cancer Center |
Thomas Jefferson University Hospital |
University of Virginia Cancer Center |
Mayo Clinic Cancer Center LAO |
Mayo Clinic |
Mayo Clinic in Arizona |
Mayo Clinic Hospital |
Mayo Clinic in Florida |
University of Maryland/Greenebaum Cancer Center |
University of Iowa/Holden Comprehensive Cancer Center |
Columbia University/Herbert Irving Cancer Center |
National Cancer Institute LAO |
National Cancer Institute Developmental Therapeutics Clinic |
National Institutes of Health Clinical Center |
NCI Center for Cancer Research |
Duke University - Duke Cancer Institute LAO |
Duke University Medical Center |
Washington University School of Medicine |
Barnes-Jewish Hospital |
Barnes-Jewish West County Hospital |
Siteman Cancer Center-South County |
UNC Lineberger Comprehensive Cancer Center |
Rutgers University - Cancer Institute of New Jersey LAO |
Rutgers Cancer Institute of New Jersey |
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital |
University of Wisconsin Hospital and Clinics |
Ohio State University Comprehensive Cancer Center LAO |
Ohio State University Comprehensive Cancer Center |
JamesCare at Ohio State University Hospital East |
Stefanie Spielman Comprehensive Breast Center |
JamesCare Gynecologic Oncology at Mill Run |
Case Western Reserve University |
Cleveland Clinic Foundation |
University of Kentucky/Markey Cancer Center |
University of Pittsburgh Cancer Institute LAO |
University of Pittsburgh Cancer Institute (UPCI) |
UPMC-Montefiore Hospital |
University of Pennsylvania/Abramson Cancer Center |
University of Florida Health Science Center - Gainesville |
University of Texas MD Anderson Cancer Center LAO |
M D Anderson Cancer Center |
University of Colorado Cancer Center - Anschutz Cancer Pavilion |
*LAO = Lead Academic Organization
NCI Early Drug Development Opportunity Program (EDDOP)
Beginning in 2016, investigators from certain NCI-designated Cancer Centers not affiliated with the ETCTN may submit a Letter of Intent (LOI) and, if approved, receive full ETCTN support for the clinical trial. Non-ETCTN NCI Cancer Centers will also be able to compete for administrative supplements to enroll patients on select ETCTN phase 2 trials. Click here for more information about the EDDOP.
Other ETCTN-affiliated Networks
Other consortia which participate in ETCTN trials are:
NCI-sponsored Infrastructure for ETCTN Trials
ETCTN trials are supported by integrated centralized clinical and administrative services sponsored by NCI. More details, and links to each service, may be found here.